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Abstract 
Hepatitis C virus (HCV) envelope glycoproteins, E1 and E2, are involved in the 
first steps of virus infection. The E2 ectodomain can be produced as an isolated 
form (E2661). However, there is some concern about its proper conformation and 
the role that E1 can play as a chaperone for the folding of E2. In order to verify 
this fact we have expressed a chimeric protein (E1tmbE2) based on the full-
length E1 sequence followed by the E2 ectodomain using the baculovirus-insect 
cells system. The E2 ectodomain is folded in the presence of the E1, 
proteolytically processed by cellular proteases and secreted to cell culture 
media (E2661p), while the E1 protein is retained into the cell due to its 
transmembrane sequence. The purification of E2661p from culture media was 
facilitated by a His tag introduced in its amino terminus. Both E2661 and E2661p 
glycoproteins shared very similar structural features, monitored by 
spectroscopic and antigenic studies. Moreover, their functional properties, 
tested by means of CD81 binding, were almost indistinguishable, indicating that 
the E2 ectodomain constitutes an independent folding unit. 
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Highlights: 1. The ectodomain of E2 was folded in a native conformation in the 
presence of E1. 2. Its properties are the same than those of the ectodomain 
folded in the absence of E1. 3. E2 ectodomain behaves as an independent 
folding unit. 
 
 
Abbreviations: Hepatitis C Virus (HCV), HCV E2 envelope protein ectodomain 
folded in the absence of E1 (E2661), HCV E2 envelope protein ectodomain 
folded in the presence of E1 (E2661p), cell-cultured HCV (HCVcc), CD81 Large 
Extracellular Loop (CD81-LEL), Convex Constraint Analysis (CCA).
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Introduction 
 
Hepatitis C virus (HCV) is a positive sense, single-stranded RNA virus 
belonging to the Hepacivirus genus of the Flaviviridae family. HCV infection is a 
major cause of liver disease, having a high propensity for establishing a chronic 
infection [1]. In the search of a future first vaccine for HCV, a possible strategy 
is to abolish the initial steps of the HCV infection. In this regard, HCV entry is a 
highly orchestrated process mediated by viral envelope glycoproteins E1 and 
E2 and several host factors including heparan sulfate, the tetraspanin CD81, 
the scavenger receptor BI, the tight junction proteins claudin-1 and occludin, the 
Niemann-Pic C1-like 1 cholesterol absorption receptor and other factors 
(reviewed in [2]) . 
HCV envelope glycoproteins E1 and E2 are components of the viral 
spike which play an essential role in virus entry into host cells by interacting with 
cell surface receptors and inducing fusion between the viral and cellular 
membranes [3, 4]. E2 is the primary glycoprotein responsible for receptor 
interaction, while little is known about the exact role of E1 protein. They are type 
I transmembrane glycoproteins, highly glycosylated, with a large N-terminal 
ectodomain and a C-terminal transmembrane domain. There are reports which 
indicate that E1 and E2 may assist each other for correct folding in such a way 
that E2 assists E1 by stabilizing a semi-native conformation meanwhile E1 
drives E2 towards a productive folding pathway [5-9]. These observations would 
indicate that HCV envelope glycoproteins cooperate to form a functional 
complex. However, E2 protein acquires a three dimensional structure 
compatible with a native conformation when it is expressed as an isolated form 
[6, 9] which can block HCV infection in vitro [10]. Moreover, recent studies 
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carried out with E2 ectodomain (residues 384-661 of the polyprotein) produced, 
either in insect [11] or in mammalian cells [10], have shown that E2 can act as 
an independent folding unit. Structural characterization of the E2 ectodomain by 
means of circular dichroism [10-12] and infrared spectroscopy [12], indicates 
that E2 is mainly constituted by β-sheet and non-ordered structures. Based on 
gene organization HCV E2 envelope glycoprotein has been classified as a class 
II fusion protein [13]. One feature of these polypeptides is that they fold as a 
heterodimer with the previous glycoprotein in the precursor polyprotein. Thus, 
the first protein in the tandem (E1) would act as a chaperone for the folding of 
the second one (E2) which is the fusion protein. However, very recently the 
structure of the core ectodomain of E2 bound to an antigen-binding fragment 
has been described [14, 15]. The structure differs clearly from the extended 
conformation of class II fusion proteins being organized as a compact domain 
composed mainly of β-strands. 
The fact that E1 may have some role as a chaperone for the folding of E2 
can be exploited to produce E2 ectodomain in a higher proportion. To this end, 
we have designed a chimeric construct in which full-length E1 sequence is 
followed by the E2 ectodomain (E1tmbE2 construct). The expression of this 
construct by using the baculovirus-insect cells system allowed the folding of the 
E2 ectodomain in the presence of the E1 protein, and after proteolytic 
processing, its secretion and purification from cell culture medium. In this paper 
we describe the characterization of this protein, named as E2661p, and compare 
its structural and functional properties with those of the E2 ectodomain folded in 
the absence of E1 (E2661) [10-12].  
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Materials and Methods 
Plasmid constructs. Construct of pAcGP67-A-E2661 (residues 384-661) 
plasmid has been previously described [11]. pAcGP67-A-E1tmbE2 plasmid was 
constructed using pAcGP67-A-E1E2746 plasmid as template. This plasmid 
comprises E1 (residues 192-383) and E2 (residues 384-746) complete 
sequences, and it has a His tag in the amino terminal region of E1. Two PCR 
reactions were carried out in parallel using the same template. For the first one 
we used the following primers: 5´-G CGA CAT GTC CAT CAC CAT CAC CAT 
CAC GAA ACC CAC GTC ACC GGG-3´ (forward), which introduces a His tag 
in the N-terminus of E2 ectodomain and PciI restriction site and 5´-GC GGA 
TCC GCG GCC GCT TCA CTC GGA CCT GTC CCT GT-3´ (reverse), which 
hybridizes with 3´end of E2 ectodomain. The second reaction was performed 
with these two primers: 5´-CAA GAT GGT AAG CGC TAT TG-3´ (forward; 
nucleotides 4185-4204 of pAcGP67-A plasmid), which hybridizes with GP67 
sequence of the plasmid, that is located upstream E1 sequence, and 5´-A AGC 
TTA CAC ATG TGT TTC CGC GTC GAC GCC-3´ (reverse), which allows to 
introduce the first four aminoacids of E2 after E1 sequence and a PciI restriction 
site. These two PCR amplified fragments were digested with PciI restriction 
enzyme, and ligated. A second PCR reaction was carried out to amplify the 
cDNA ligated with border primers. Amplified cDNA was digested with adequate 
restriction enzymes (EcoRI/NotI) and ligated in pAcGP67-A plasmid digested 
with the same enzymes. HCV envelope proteins sequence corresponds to 
genotype 1a, strain PT. 
 
Protein expression and purification. The recombinant E1tmbE2 construct 
was expressed in Tni insect cells infected with recombinant baculovirus 
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obtained after transfection with the pAcGP67A-E1tmbE2 plasmid and the 
linearized viral DNA. Insect cells were grown in X-Press serum-free media prior 
to infection with high titer virus (>108 pfu/ml) at a multiplicity of infection of 5-10. 
Four days after infection, the cells were harvested and centrifuged at 5000 rpm 
for 10 min and the supernatant dialyzed against 10 mM Tris-HCl pH 7.0, 50 mM 
NaCl. The chimera E1tmbE2 was proteolitically processed inside the Tni insect 
cells. The secreted E2661p glycoprotein was purified from the supernatant by 
Ni2+-nitrilotriacetic acid agarose chromatography, according to methods 
previously described for the expression and isolation of E2661 [11]. 
    
Protein analysis. Protein concentration was determined 
spectrophotometrically from the absorbance at 280 nm and the extinction 
coefficient calculated from the amino acid analysis. The absorption spectra 
were recorded on a Beckman DU-640 spectrophotometer. The amino acid 
analysis of hydrolyzed aliquots was performed on a Beckman 6300 automatic 
analyzer. Automated Edman protein degradation of E2661p was performed 
using an Applied gas-phase sequencer (model 494). 
 
Circular Dichroism. CD measurements were carried out on a Jasco 
spectropolarimeter, model J-715. All the measurements were carried out at 
room temperature. Far-UV CD spectra were measured at a protein 
concentrations of 0.1 mg/ml using protein dialyzed against 30 mM MOPS pH 
7, 100 mM NaCl. The circular cuvette pathlength was 1 mm. Five scans were 
averaged for each measurements and the contribution of the buffer was 
always subtracted. The spectra were calculated by using 110 as the mean 
residue molecular mass and the results are expressed in terms of residue 
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molar ellipticity in degree⋅cm2⋅dmol-1. The secondary structure of the protein 
was evaluated by computer fit of the dichroism spectra according to Convex 
Constraint Analysis (CCA) [16]. This method relies on an algorithm that 
calculates the contribution of the secondary structure elements that give rise 
to the original spectral curve without referring to spectra from model systems. 
The secondary structure was also predicted from the amino acid sequence by 
the GOR IV method [17].  
 
Fluorescence spectroscopy. Emission spectra were obtained at 25ºC using 
an SLM AMINCO 8000C spectrofluorimeter, fitted with a 450-W xenon arc. 
Excitation and emission slit widths were set at 4 nm. The protein 
concentration was 0.05 mg/ml and a 0.2 x 1 cm cuvette was used. Buffer was 
30 mM MOPS, pH 7.0, 100 mM NaCl. Excitation was performed at 275 or 295 
nm, and the emission spectra were recorded over the range 285-450 nm. The 
contribution of the buffer was always subtracted. The tyrosine contribution to 
the emission spectra was calculated by subtracting the emission spectrum 
measured at λexc = 295 nm multiplied by a factor from that measured at λexc = 
275 nm. The factor was obtained from the ratio between the fluorescence 
intensities measured with λexc = 275 and λexc = 295 nm at wavelengths above 
380 nm, where there is no tyrosine contribution. 
 
 SDS-PAGE.  Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed according to Laemmli using 
15% polyacrylamide gels [18]. Samples were subjected to gel electrophoresis 
under either nonreducing or reducing conditions (with 5% (v/v) β-
mercaptoethanol) and the proteins were stained with Coomassie brilliant blue 
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R-250. The molecular mass of the protein bands was estimated by 
comparison with protein markers of known molecular mass (Prestained SDS-
PAGE Standards, Bio-Rad). 
 
Western blotting. After SDS-PAGE, proteins were transferred to 
nitrocellulose membranes (Hybond-ECL; Amersham) in 48 mM Tris-HCl pH 
9.0, containing 39 mM glycine, 0.0375% SDS and 20% (v/v) methanol, for 1 h 
at 1 mA/cm2, by using a V20-SDB apparatus (Scie-Plas). To detect proteins, 
membranes were incubated for 16 h at 4ºC either with a HRP-conjugated 
monoclonal anti-His antibody (Sigma) at a 1:3000 dilution or with a polyclonal 
goat anti-E2 antibody (US Biologicals) at a 1:500 dilution, or with the A4 
monoclonal anti-E1 antibody (kindly provided by Dr. Jean Dubuisson, Intitut 
Pasteur de Lille, France) at a 1:1000 dilution. In the case of incubations with 
anti-E2 and anti-E1 antibodies, membranes were washed and incubated for 1 
h at room temperature with the corresponding secondary antibodies, HRP-
conjugated rabbit anti-goat (Jackson Immunoresearch) or goat anti-mouse 
IgG (Sigma) at a 1:3000 dilution. Membranes were developed with ECL 
reagents (Amersham Life Sciences) and exposure to photographic film.  
 
Enzyme Linked Immunosorbent Assay (ELISA). 96 wells microtitre plates 
(Nunc F96 maxisorp) were coated overnight at 4ºC with 100 ng/well of 
purified recombinant protein diluted to 1 µg/ml in PBS. Unbound antigen was 
discarded, and the wells were blocked with 3% non-fat dry milk in PBS for 60 
min at room temperature. After washing the wells were incubated at 37ºC for 
2 h with human serum. Six HCV-positive human sera and ten HCV-negative 
human sera were used at a dilution of 1:100-1:500. The plates were washed 
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three times with PBS/0.05% Tween 20 and incubated at 37 ºC for 1 h with 
HRP-conjugated anti-human IgG (Fc) (Sigma) diluted at 1:10000. Bound 
antibodies were detected by adding 100 mM sodium citrate pH 5.0, 4% 
Methanol buffer containing H2O2 and the substrate o-phenylenediamine 
dihydrochloride (OPD) (Merck). The optical density at 490 nm was measured 
using an ELISA Expert 96 microplate reader (ASYS Hitech). Sera from 
infected and control patients were provided by Dr. Fernando Vivanco 
(Fundación Jiménez Díaz, Madrid, Spain).   
For H53 ELISA assays, the same protocol was followed but with these 
exceptions: 96 well plates were coated with 1 µg /well of purified protein. E2 
was detected with H53 antibody at a 1:400 dilution and a goat anti-mouse-
HRP conjugated antibody (Sigma) at a 1:3000 dilution. The monoclonal 
antbody H53 is conformation-dependent and was kindly provided by Dr. Jean 
Dubuisson (Intitut Pasteur de Lille, France). 
 
LEL-CD81 binding assay A 100 µl aliquot of a 3 µg/ml solution of 
glutathione S-transferase (GST) fusion protein expressing the second 
extracellular region (EC2) of the LEL of human CD81 (GST-hLEL) [19] was 
used to coat each well of a Nunc F96 Maxisorp, 96 well-plate and incubated 
overnight at room temperature. Unbound protein was discarded, and the wells 
were blocked with 2% non-fat dry milk in PBS/0.05% Tween 20 for 2 h at room 
temperature. After washing the wells with PBS/0.05% Tween 20, 100 µl of 
soluble E2 protein at different concentrations (0-10 µg/ml) was incubated with 
bound LEL-CD81 protein at room temperature for 2 h. LEL-CD81 bound E2 
protein was detected using H53 antibody followed by a HRP-conjugated goat 
anti-mouse IgG (Sigma) at a 1:3000 dilution for 1 h at room temperature. 
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Detection was performed by adding 100 mM sodium citrate pH 5.0, 4% 
Methanol buffer containing H2O2 and the substrate OPD (Merck). The optical 
density at 490 nm was measured. 
  
 
12
Results and Discussion  
 
E2661p expression and purification. Previous studies using S2 Drosophila 
cells have demonstrated that a truncated form of E2 can be processed and 
secreted after expression of a polypeptide containing the HCV envelope 
genome lacking the E2 transmembrane domain (E1-E2∆TM) [12]. Following a 
similar procedure we have designed the chimera E1tmbE2 (Fig. 1). After the 
full-length E1 sequence this polypeptide contains an N-terminal His-tagged E2 
ectodomain, in order to facilitate the purification of the processed E2661p, that 
should be almost identical to the previously described E2661 [11]. 
The intra and extracellular expression of E1 and E2 proteins by Tni 
infected cells was evaluated using anti-E1, anti-E2 and anti-His antibodies by 
western blot (Fig. 2a). The theoretical masses of E1 and E2661p based on the 
amino acid sequences are 22 and 32 kDa respectively. It can be observed that 
the E1tmbE2 polypeptide was proteolytically processed by cellular proteases to 
generate the E2 ectodomain. This domain was partially secreted to the 
extracellular medium, while the E1 protein was retained into the infected cells. 
The secreted E2 ectodomain folded in the presence of E1 was named as E2661p 
in order to distinguish it from E2661, folded in the absence of E1 [11]. 
Intracellular E1 and E2 fractions presented complex patterns of bands, probably 
due to unfolded and non-processed proteins and even proteolytically cleaved 
proteins with different glycosylation degrees. E2661p protein secreted to the 
extracellular medium was subsequently purified using affinity chromatography 
on a Ni2+–nitrilotriacetic acid-agarose column. The protein that elutes with 200 
mM imidazole had a purity higher than 95% upon densitometry of stained SDS 
gels (Fig. 2b). The purified protein was recognized by monoclonal anti-His and 
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goat anti-E2 antibodies (Fig. 2b). Following this procedure, approximately 1 mg 
of E2661p glycoprotein was obtained from 1 L of culture media. This low yield of 
purification compared to that of E2661 (5-6 mg/ L culture medium [11]) could be 
due to the lower secretion levels after improper processing of the chimeric 
protein and/or interaction of E2 with E1 retained in the insect cells.  
 
Biochemical characterization of E2661p. The Edman degradation of purified 
E2661p confirmed that the amino-terminal sequence was ETHVHHHHHH, 
indicating that the E1tmbE2 polypeptide was properly processed after residue 
383 of E1. The sequence ETHV corresponds to residues 384-387 of E2. 
 SDS-PAGE of recombinant E2661p in the presence of reducing agents 
showed a single band with a molecular mass of 48 kDa (Fig. 3a), coincident 
with that of E2661 but higher than the theoretical mass based on the amino 
acid sequence. Based on the fact that E2661 can be partially deglycosilated by 
N-glycosydase F [11] it can be suggested that both E2661 and E2661p proteins 
have a similar glycosylation pattern, and possibly an analogous folding 
process. In the absence of reducing agents, E2661 and E2661p migrate in 
SDS-PAGE as at least four bands corresponding to monomers, dimers, 
trimers and tetramers (Fig. 3b), suggesting that oligomers are constituted by 
disulfide bonds linked monomers. The trend in oligomer distribution is 
maintained in the different preparations obtained. Nevertheless, the amount 
of monomers observed in the case of E2661p is higher than in E2661 protein 
(Fig. 3b). This result could be explained because E2661p is more diluted in the 
extracellular medium and, hence, intermolecular interactions should occur 
with less probability. A second possible explanation could be that small 
conformational changes in the regions implied in oligomerization were taking 
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place when E2 is folding in the presence of E1, leading to lower interaction 
between monomers. If this were the case, E1 would have a chaperone-like 
role in the folding of E2. 
 
Spectroscopic characterization of E2661p. The spectroscopic 
characterization of E2661p was carried out by means of circular dichroism and 
fluorescence spectroscopies. The spectra were taken in parallel with E2661 in 
order to check if folding in the presence of E1 induces conformational 
changes in E2 ectodomain. The far-UV CD spectrum of both proteins showed 
a minimum at 206 nm (Fig. 4a). Deconvolution of these spectra using the 
program CCA [16] yielded the percentages of secondary structure elements 
showed in Table 1. As observed, both proteins showed a very similar 
secondary structure pattern, with a low helical content being the β-sheet the 
main ordered structure. The predictive GOR IV method [17], which is based 
upon the propensity of each amino acid to adopt a particular secondary 
structure yielded basically similar results (theoretical, Table 1). Also, these 
results agree well with the recently published structure of the core of E2 
ectodomain [14, 15]. Morevover, these results show that there are no 
changes in terms of secondary structure when the E2 ectodomain is folded in 
the presence of E1. 
Fluorescence emission spectrum of E2661p showed a maximum at 332 
nm upon excitation at 275 nm, which is 2 nm lower than that exhibited by 
E2661 which is centered at 334 nm (Fig. 4b). In both cases, the difference 
between the fluorescence spectra obtained upon excitation at 275 and 295 
nm, the latter being normalized, indicated that the contribution of tyrosine 
residues to the emission fluorescence upon excitation at 275 nm was very 
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low, approximately 5 % (Fig. 4b). Thus, we can conclude that in both proteins 
the Trp residues are located in a very similar environment of relatively low 
hydrophobicity. Nevertheless, as denoted by the 2 nm shift of the maximum 
to lower wavelength, E2661p fluorophores could be located in a barely more 
non polar microenvironment than the E2661 ones, as a result of a slightly more 
compact folding of E2 ectodomain in the presence of E1. This observation 
would be in accordance with the lower tendency of E2661p to aggregate, since 
a more compact conformation diminishes the surface exposition of 
hydrophobic domains and, thus, reduces the probability of intermolecular 
interactions.  
 
Antigenic characterization of E2661p. A panel of six HCV-positive and ten 
HCV-negative human sera was used to assess the antigenic properties of 
E2661p, following the ELISA described in Methods. E2661p and E2661 proteins 
were able to bind to antibodies present in the six HCV-positive human sera 
(Fig. 5, sera 1, 2, 3, 4, 5 and 6) at different levels, whereas they were not 
recognized by immunoglobulins from HCV-negative sera (Fig. 5, sera 7-8; 
only two of the ten negative sera are depicted). The reactivity pattern was 
very similar in both cases. However, it must be noted that the mean signal 
obtained with E2661p is about 30% lower than the observed with E2661. This 
result could indicate that the protein folded in presence of E1 has a lower 
exposition of its epitopes, probably as a consequence of its slightly more 
compact conformation. 
Moreover, the reactivities of both proteins with the anti-E2 
conformation-dependent H53 monoclonal antibody were almost identical (Fig. 
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5, inset).  Again, these results suggest that both E2661 and E2661p possess 
very similar conformations. 
 
Binding of E2661p to CD81-LEL. The specific interaction with the human 
tetraspanin CD81-LEL region has been regularly used to monitor the functional 
properties of HCV E2 glycoprotein [20, 21]. Using a recombinant human CD81-
LEL (residues 116-202) fusion protein with GST (Glutathione S-Transferase), 
an ELISA binding assay has been performed with both E2661 and E2661p 
proteins. The results shown in Fig. 6 indicate that both recombinant 
glycoproteins bind to CD81-LEL in a concentration dependent manner, with 
almost identical reactivity. Although the interaction of CD81 is specific for E2, 
recent studies using E1-cysteine mutants in cell-cultured HCV (HCVcc) 
indicated that E1 glycoprotein has a modulating effect in the binding of E2 to 
CD81 [22]. However, this effect must be restricted to the context of the E1E2 
heterodimer, since the isolated E2 ectodomain has the same CD81-binding 
capacity when it folds either independently (E2661) or in the presence of E1 
(E2661p).   
To sum up, the results shown herein, carried out with isolated and 
soluble recombinant proteins, highlight that the presence of E1 is indeed not 
necessary for the correct folding of the E2 ectodomain, since E2661 and E2661p 
presented very similar structural, antigenic and functional characteristics. 
Although there are reports in the literature that also support the independent 
folding of E2 ectodomain, most of them are based on mammalian cell culture 
transient expression assays with viral and non-viral vectors. Thus, using Sindbis 
and vaccinia virus vectors, Michalak et al. [6] showed that the folding of E2 is 
independent of E1, but E2 is required for the proper folding of E1. The effect of 
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co-expression of E1 and E2 glycoproteins on each other’s folding was 
evaluated after immunoprecipitation of the expressed proteins from different 
mammalian cell culture supernatants with the help of a conformation-sensitive 
monoclonal antibody (for E2) or by analysing intramolecular disulfide bond 
formation (for E1). The fact that E2 ectodomain could be expressed 
independently of the polyprotein and that it folds in a structure able to bind to 
cellular receptors [23, 24] is a further evidence of its independent folding.  
One strategy to increase the quantity and even the quality of recombinant 
proteins using the baculovirus-insect cells system has been to co-express them 
with a chaperone. Thus, it has been described that co-expression of both 
protein disulfide isomerase and the chaperone BiP increased the solubility and 
secretion of immunoglobulin G from insect cell [25, 26]. The postulated 
chaperone-like function of E1 is not translated into higher quantity but its co-
expression gives rise to a slightly more compact E2 ectodomain with a lower 
tendency to form disulfide-bridge oligomers. In this regard, there is some 
controversy with respect the functionality of the HCV envelope glycoproteins 
and the formation of intermolecular covalent complexes. On the one hand, in 
cells expressing recombinant HCV glycoproteins, E1 and E2 proteins have 
been shown to form both E1E2 noncovalent heterodimers and large covalent 
E1E2 complexes, with the latter corresponding to nonfunctional aggregates 
while the former representing the possible functional unit for HCV entry [27]. On 
the other hand, more recently it has been described by using the HCVcc system 
the selective incorporation into secreted virions of large E1E2 disulfide-linked 
complexes that maintain a native conformation as they were able to bind 
conformation-sensitive neutralizing antibodies [28]. Furthermore, a recombinant 
chimeric protein based on the E1 and E2 ectodomains (E1341E2661) was 
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produced in the baculovirus system with native-like properties in spite of having 
a high tendency to self-associate by forming intermolecular disulfide bridges 
[29]. Then, the disulfide-bridge oligomerization of HCV envelope glycoproteins 
seems to be compatible with the maintenance of their native properties. The 
results presented in this work, although related to a processed glycoprotein 
(E2661) instead of the E1E2 heterodimer, confirm this point of view. Moreover, 
the E2 ectodomain folded in the absence of E1, which can be produced with a 
much higher yield and with a higher degree of disulfide-linked complexes [11], 
showed a 30% increased ability to bind to human antibodies, making this 
recombinant protein potentially suitable for developing future HCV vaccines. 
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Table 1. Percentages of secondary structure of E2661 and E2661p. Experimental 
secondary structure percentages were calculated using CCA method [16] from 
far-UV CD spectra, while theoretical values were obtained using GOR IV 
method [17] for three components. 
 
 
 
 
 
 
% Secondary 
Structure 
Experimental Theoretical 
E2661 E2661p  
α-helix 2 7 2 
β-sheet 50 53 34 
Non ordered 48 40 64 
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Figure Legends 
  
Fig. 1. Schematic representation of E1tmbE2 construct. The construct has a His 
tag in the N-terminal ends of both E1 and E2 proteins. E1 sequence is 
complete, including its transmembrane domain (tmb), while E2 sequence is 
truncated at 661 residue (E2 ectodomain). The first four residues of E2 (384-
387) (ETHV) were included after E1 sequence and before the His tag of E2, in 
order to ensure a proper proteolytic cleavage after residue 383 of E1. 
 
Fig. 2. Expression and purification of E2661p protein. (a) Western blot analysis of 
the extracellular (E) and the intracellular (l) E1 and E2 proteins produced by 
baculovirus-infected insect cells. The presence of both proteins was detected 
with a polyclonal anti-E2 antibody, a monoclonal anti-His antibody and a 
monoclonal anti-E1antibody. The arrows indicate the position of the 
corresponding molecular mass marker. A control (C) of uninfected cells is 
shown. (b) SDS-PAGE (Coomassie brilliant blue R-250 staining) and western 
blot analysis (with a monoclonal anti-His antibody and a polyclonal anti-
E2antibody) of purified E2661p recombinant protein. The samples were 
previously reduced with 5% (v/v) β-mercaptoethanol and boiled for 5 min. The 
blots were developed with ECL reagents as indicated in the Materials and 
Methods section. The results shown are representative of those obtained for 
three different experiments. 
 
Fig. 3. Oligomeric state of E2661p. Purified E2661p protein was subjected to SDS-
PAGE in the presence (a) or absence (b) of the reducing agent β-
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mercaptoethanol. E2661 purified protein was used as reference. The arrows 
indicate the position of the corresponding molecular mass marker. (1) 
Monomer, (2) dimer, (3) trimer and (4) tetramer. The gel was stained with 
Coomassie brilliant blue R-250. The results shown are representative of those 
obtained for three different experiments. 
 
Fig. 4. Spectroscopic characterization of E2661p. (a) Far-UV CD spectra of E2661 
(——)
 
and E2661p (- - -) at pH 7.0. The spectra were recorded between 190 and 
250 nm with a protein concentration of 0.1 mg/ml in a cylindrical cuvette of 0.1 
cm pathlength. Spectra were recorded five times, averaged and corrected for 
buffer contributions. Data are expressed as mean residue molar elipticity. (b) 
Fluorescence emission spectra of E2661 (——) and E2661p ( - - -) at pH 7.0 upon 
excitation at 275 nm. The Tyr contribution, calculated as described in Materials 
and Methods, is also shown, E2661 (· ·  ·) and E2661p (-· ·-· ·). The protein 
concentration was 0.05 mg/ml. The buffer employed was 30 mM MOPS pH 7.0, 
100 mM NaCl and its contribution was always subtracted. Spectra were 
collected at room temperature. The spectra shown are representative of those 
obtained for three different protein preparations. The results shown are 
representative of those obtained for three different experiments. 
 
Fig. 5. Reactivity of E2661 and E2661p against HCV-positive (1-6 sera) and 
negative human sera (7 and 8 sera). 96-well plates were coated with 100 ng of 
purified recombinant protein/well. After washing the wells were incubated with 
the sera diluted between 1:100-1:500. Absorbance signals were normalized 
according to the A490 provided by E2661 with serum nº 4 which gave the highest 
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signal. 10 negative sera were assayed and all of them provided the same 
reactivity as that obtained with sera 7 and 8. (Inset) Reactivity of E2661p and 
E2661 against H53 conformation-dependent monoclonal antibody. Protein buffer 
contribution was subtracted. Means and SD of three independent experiments 
are shown. 
 
Fig. 6. Binding of E2661 and E2661p to human CD81-LEL. 96-well plates were 
coated with 300 ng of CD81-LEL/well. After washing, soluble E2 protein was 
added at different concentrations and incubated for 2 h at room temperature. 
H53 and goat anti-mouse-HRP conjugated antibodies were used to detect E2 
bound protein. Protein buffer contribution was subtracted. Values were 
normalized according to the A490 provided by E2661 at 10 µg/ml. Means and SD 
of three independent experiments are shown. 
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